AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
Related topics
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

BioTek reMEDys Promotes Awareness and Education for Myositis

May 26, 2021 GMT

NEW CASTLE, Del.--(BUSINESS WIRE)--May 26, 2021--

In honor of May being Myositis Awareness Month, BioTek reMEDys, one of the nation’s largest independent specialty infusion pharmacies focused on rare diseases, is calling for enhanced education and awareness of the condition.

Myositis is a muscle-wasting disease that results in fatigue and reduced strength. With inadequate or no treatment, myositis can cause significant disability and even death. BioTek reMEDys is urging its clinical and patient constituents and the population at large to become more aware and get involved in drawing awareness to the often underdiagnosed condition.

ADVERTISEMENT

It’s common for myositis patients to wait more than three-and-a-half years and see five doctors before receiving a correct diagnosis,” said Carla Sparkler, BioTek reMEDys’ Chief Marketing Officer. “At BioTek reMEDys we are proud to be one of the very few organizations today that serves this specific community of patients through our specialty infusion services.

“We’ve seen many examples of significant disease damage during this wait, not to mention the worry and stress it causes patients and their families,” added Sparkler. “There is also a lot of confusion over how to effectively manage patients with myositis and currently no cure. In most cases, aggressive treatment is required. Our hope is that patients and their loved ones will make their voices heard via social media to help expand the world’s understanding of myositis, and through awareness, lead to shortened waits between symptoms and diagnosis.”

On the weekend of May 29 th - 30 th, the Myositis Association will conduct a dedicated Myositis Awareness Month social media takeover. BioTek reMEDys is encouraging myositis patients, their loved ones, and all supporters of people living with the condition to post on their social media accounts and spread the word by using the hashtags #myositis, #TMA, and #themyositisassociation. BioTek is urging all of its constituents to like, comment, follow and share patients’ Facebook pages, Instagrams and tweets to offer support and help build a compassionate and supportive community.

ADVERTISEMENT

BioTek reMEDys is also encouraging the general public to visit the Myositis Support and Understanding Association’s web page to learn more about the condition and explore other ways to support those living with the condition.

BioTek reMEDys provides therapy-specific patient education materials and its National Customer Support Center is available 24 hours a day, 7 days a week to help patients and their loved ones manage critical aspects of care. By servicing very specific disease states such as myositis, BioTek reMEDys’ expert team can maintain its focus on patient care – making sure that dosages and treatments are appropriate.

Founded in 2011, BioTek reMEDys, based in New Castle, DE, has become one of the nation’s largest independent infusion pharmacies focused on home infusion. Chai Gadde opened the pharmacy to meet the specific needs of patients who require specialty medications. BioTek reMEDys and its affiliates are now licensed to operate in all 50 states. For information visit www.biotekrx.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20210526005937/en/

CONTACT: Media Contact:

Paul Williams

paul@medialinecommunications.com

310/569-0023

KEYWORD: UNITED STATES NORTH AMERICA DELAWARE

INDUSTRY KEYWORD: HEALTH CONSUMER OTHER HEALTH PHARMACEUTICAL OTHER EDUCATION OTHER PHILANTHROPY PHILANTHROPY OTHER SCIENCE RESEARCH EDUCATION GENERAL HEALTH OTHER CONSUMER FOUNDATION SCIENCE

SOURCE: BioTek reMEDys

Copyright Business Wire 2021.

PUB: 05/26/2021 12:50 PM/DISC: 05/26/2021 12:51 PM

http://www.businesswire.com/news/home/20210526005937/en